MarketPeel
Insider Trading Intelligence
OG

Oren Gilad

APRE
PRESIDENT/CEO · APREA THERAPEUTICS, INC. · CIK 0001929300
FILING MIX · LIFETIME96%/4%
BUYS
24
SELLS
1
TOTAL VALUE
$80.4K
COMPANIES
1
ACTIVE SINCE
Jul 2022
HOLDINGS NOW
393,895
AVG SELL PX
TRADE KIND
SHOWING 25 / 25
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
13 backtested trades · 8 horizons · 16 pending
Forward-return performance of every backtestable P/S trade by Oren Gilad, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d13+53.85%+13.81%-0.32%+14.13%+2.47%
14d13+69.23%+9.32%+0.13%+9.19%+3.87%
30d13+92.31%+7.39%+1.60%+5.79%+3.57%
60d13+46.15%-1.30%+2.33%-3.63%-0.55%
90d13+46.15%+1.38%+4.37%-3.00%-7.37%
180d13(2 pending)+0.00%-34.60%+4.02%-38.62%-42.18%
1y13(4 pending)+0.00%-54.38%+14.41%-68.79%-65.45%
2y13(10 pending)+0.00%-86.74%+30.39%-117.13%-117.13%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
APRE · 393,895 shares · as of Mar 12, 2026
01,593,8543,187,7074,781,5616,375,4142023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 24 buys / 1 sellsCOVERAGE · 15 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
80,70080,700Mar 12, 2026Mar 16, 2026View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,175393,895Mar 12, 2026Mar 16, 2026View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
President/CEO
28,10028,100Jan 30, 2026Feb 2, 2026View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
President/CEO
28,100$0.89$25.0K373,720Jan 30, 2026Feb 2, 2026View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
President/CEO
21,459$1.17$25.0K21,459Dec 10, 2025Dec 11, 2025View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
President/CEO
21,45921,459Dec 10, 2025Dec 11, 2025View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
President/CEO
3,003$1.87$5.6K343,123Apr 3, 2025Apr 4, 2025View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
President/CEO
2,497$1.80$4.5K345,620Apr 3, 2025Apr 4, 2025View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,725340,120Mar 27, 2025Mar 31, 2025View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
26,90026,900Mar 27, 2025Mar 31, 2025View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
President/CEO
500$3.92$2.0K333,395Oct 23, 2024Oct 24, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
President/CEO
250$2.90$725332,895Oct 15, 2024Oct 16, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
President/CEO
1,000$2.59$2.6K332,645Oct 14, 2024Oct 15, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
President/CEO
150$2.54$381331,645Oct 10, 2024Oct 15, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,725331,495Mar 28, 2024Mar 28, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
26,90026,900Mar 28, 2024Mar 28, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
President, CEO
2,000$7.29$14.6K324,770Mar 13, 2024Mar 14, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
President, CEO
1,0001,000Mar 13, 2024Mar 14, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
President, CEO
1,0001,000Mar 13, 2024Mar 14, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,000322,770Mar 9, 2023Mar 13, 2023View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
16,00016,000Mar 9, 2023Mar 13, 2023View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
President, CEO
6,045,1006,375,414Aug 23, 2022Mar 13, 2023View →
APRE
APREA THERAPEUTICS, INC.
SALE
President, CEO
604,5100Aug 23, 2022Mar 13, 2023View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
148,700148,700Jul 28, 2022Aug 1, 2022View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
101,300330,314Jul 28, 2022Aug 1, 2022View →
Other insiders · APRE
Loading peer insiders…
About this filer
CIK 0001929300
ROLE
President/CEO
PRIMARY
APRE
COMPANIES
1
ACTIVE SINCE
Jul 2022
MARKETPEEL · /INSIDER/0001929300DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback